Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Addressing Involuntary Movements in Tardive Dyskinesia

ClinicalTrials.gov ID: NCT02291861

Public ClinicalTrials.gov record NCT02291861. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia

Study identification

NCT ID
NCT02291861
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Auspex Pharmaceuticals, Inc.
Industry
Enrollment
298 participants

Conditions and interventions

Interventions

  • SD-809 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 30, 2014
Primary completion
Aug 18, 2016
Completion
Aug 18, 2016
Last update posted
Jun 22, 2026

2014 – 2016

United States locations

U.S. sites
53
U.S. states
24
U.S. cities
46
Facility City State ZIP Site status
Teva Investigational Site 145 Tuscaloosa Alabama 35404
Teva Investigational Site 107 Anaheim California 92804
Teva Investigational Site 108 Anaheim California 92805
Teva Investigational Site 123 Glendale California 91206
Teva Investigational Site 177 Imperial California 92251
Teva Investigational Site 160 Irvine California 92614
Teva Investigational Site 106 Irvine California 92697
Teva Investigational Site 176 Loma Linda California 92354
Teva Investigational Site 121 Los Angeles California 90033
Teva Investigational Site 147 Los Angeles California 90095-1769
Teva Investigational Site 174 Norwalk California 90650
Teva Investigational Site 170 Oceanside California 92056
Teva Investigational Site 102 Orange California 92868
Teva Investigational Site 104 San Bernardino California 92408
Teva Investigational Site 110 San Diego California 92108
Teva Investigational Site 169 San Rafael California 94901
Teva Investigational Site 129 Englewood Colorado 80113
Teva Investigational Site 139 New Haven Connecticut 06519
Teva Investigational Site 156 Washington D.C. District of Columbia 20007
Teva Investigational Site 157 Boca Raton Florida 33486
Teva Investigational Site 117 Gainesville Florida 32607
Teva Investigational Site 150 Lake City Florida 32025
Teva Investigational Site 153 Miami Florida 33135
Teva Investigational Site 162 Miami Florida 33165
Teva Investigational Site 112 Orlando Florida 32803
Teva Investigational Site 144 Port Charlotte Florida 33980
Teva Investigational Site 155 Augusta Georgia 30912
Teva Investigational Site 165 Decatur Georgia 30033
Teva Investigational Site 131 Chicago Illinois 60611
Teva Investigational Site 113 Chicago Illinois 60612
Teva Investigational Site 164 Kansas City Kansas 66160
Teva Investigational Site 154 Baltimore Maryland 21287
Teva Investigational Site 101 Glen Burnie Maryland 21061
Teva Investigational Site 135 Boston Massachusetts 02215
Teva Investigational Site 118 Creve Coeur Missouri 63141
Teva Investigational Site 142 Kansas City Missouri 64108
Teva Investigational Site 175 St Louis Missouri 63104
Teva Investigational Site 161 St Louis Missouri 63109
Teva Investigational Site 178 Lincoln Nebraska 68526-9467
Teva Investigational Site 128 Albuquerque New Mexico 87106
Teva Investigational Site 172 Commack New York 11725
Teva Investigational Site 148 New York New York 10032
Teva Investigational Site 138 Asheville North Carolina 28805
Teva Investigational Site 146 Raleigh North Carolina 27610
Teva Investigational Site 133 Charleston South Carolina 29425
Teva Investigational Site 149 Memphis Tennessee 38163
Teva Investigational Site 151 Fort Worth Texas 76104
Teva Investigational Site 115 Salt Lake City Utah 84105
Teva Investigational Site 141 Salt Lake City Utah 84108
Teva Investigational Site 168 Burlington Vermont 05401
Teva Investigational Site 171 Charlottesville Virginia 22903
Teva Investigational Site 167 Richland Washington 99352
Teva Investigational Site 166 Waukesha Wisconsin 53188

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 53 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02291861, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 22, 2026 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02291861 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →